Intrinsic apoptosis is critical for normal physiology including the prevention of tumor formation.
Apoptotic cell death is a fundamental process that is essential for embryonic development and immune system homeostasis. BAX and BAK are members of the BCL-2 family of proteins that have essential, but redundant, functions as mediators of intrinsic apoptosis 1, 2, 3 . The activation of BAX and BAK and their consequent self-association permeabilizes the mitochondrial outer membrane (MOM) to instigate cytochrome c release and cell death 1 . While BAK is predominantly integrated into the MOM, BAX is predominantly cytosolic. Their distinct subcellular localizations may reflect different rates of "retrotranslocation" from the MOM to the cytosol 4, 5, 6 , although the precise determinants of their recruitment to the MOM to mediate cell killing are unclear. Many chemotherapeutic agents indirectly trigger BAX/BAK-mediated apoptosis whereas BH3-mimetic compounds, such as venetoclax (ABT-199), directly inhibit BCL-2 proteins to drive apoptosis 2, 7, 8 . Venetoclax, which selectively targets BCL-2, has proven highly efficacious for patients with high-risk chronic lymphocytic leukemia (CLL) leading to its approval for treating such patients 9 .
The VDAC channels (VDAC1, VDAC2 and VDAC3) are responsible for the transport of low molecular weight metabolites across the MOM including adenosine triphosphate (ATP) and adenosine diphosphate (ADP). Although genetic evidence has argued against a role for VDAC channels in mediating cytochrome c release 10 , VDACs have been proposed to influence apoptosis by interacting with BCL-2 family proteins including BCL-X L , BAX and BAK 11, 12, 13, 14 . In this regard, the prevailing dogma is that VDAC2 acts to limit apoptosis by sequestering BAK 15 .
In marked contrast to this, we identified VDAC2 in an unbiased genome-wide screen for factors required for BAX to function. In the absence of VDAC2, cell killing mediated by BAX, but not BAK, is abolished. Moreover, the interaction with VDAC2 is critical for BAX to mediate cell death in response to chemotherapeutic agents both in vitro and in vivo, as well as for BAX to limit in vivo tumor development. Our genetic and functional studies unequivocally define a critical and unique requirement for VDAC2 in the apoptotic activity of BAX.
Results

VDAC2 is required for BAX to mediate apoptosis
To identify novel regulators of apoptosis, we undertook unbiased, genome-wide CRISPR/Cas9 library screens (Fig. 1a) . Mcl1-deficient mouse embryonic fibroblasts (MEFs) were used as they readily undergo apoptosis when the remaining pro-survival proteins they express (BCL-2, BCL-X L , BCL-W) are inhibited by the BH3-mimetic ABT-737 (Supplementary Fig. 1a and b) 16 . Mcl1 Fig. 1e ), thus ruling out the possibility that protection was specific to ABT-737 treatment.
Most remarkably, the combined loss of BAK and VDAC2 (but not BAX and VDAC2) also afforded long term protection against ABT-737 ( Fig. 1e ) and A1331852 ( Supplementary   Fig. 1f ) in clonogenic assays. The critical role for VDAC2 in BAX apoptotic function extends beyond these model systems since deleting Bak in Vdac2 -/-MEFs likewise rendered these cells highly resistant to etoposide-induced apoptosis (Fig. 1f) . Collectively, our data strongly indicate that apoptosis mediated by BAX, but not BAK, requires VDAC2. Next, we asked whether VDAC2 physically interacts with BAX to promote its activity.
VDAC2 and VDAC3 are the key components of a BAX-containing mitochondrial complex
We, and others, have reported that BAX and BAK reside in large VDAC2-containing mitochondrial complexes, but become dissociated following the induction of apoptosis 12, 13, 19 . To determine whether these are identical or distinct VDAC2 complexes we performed antibody gelshift assay on mitochondrial fractions prepared from HeLa or HCT-116 cells (Fig. 2a) . We found that adding Fab fragments of an antibody that binds inactive human BAK (7D10 20 ) altered the mobility of the BAK:VDAC2 complex on a native gel. However, the BAX:VDAC2 complex was unaffected (Fig. 2a) . Hence, VDAC2 must form distinct complexes with BAX or BAK.
The sizes of these complexes on native gels also suggested that they are large multimeric complexes that could contain other components. To identify constituent proteins, we generated
MEFs stably expressing FLAG-BAX S184L or FLAG-BAK (both of which are constitutively localized to mitochondria through an interaction with VDAC2 13 ) and purified the complexes under native conditions using an anti-FLAG antibody ( Supplementary Fig. 2a ). While mass spectrometry of these complexes confirmed the presence of VDAC2 and BAX or BAK, VDAC1
and VDAC3 were also present ( Fig. 2b and c, Supplementary Tables 4 and Table 5 ). Supplementary Fig. 2e ). While deleting Vdac3 also impacted on BAX complex formation ( Fig. 2e and Supplementary Fig. 2e ), mitochondrial localization of BAX was unaffected (Fig. 2d) . Likewise, VDAC2 played an important role in the mitochondrial localization of BAK (Fig. 2d) , whilst VDAC3 played an ancillary role indicated by the modified mitochondrial complexes following Vdac3 deletion (Fig. 2e) .
These biochemical studies suggest that the constitution of the distinct mitochondrial VDAC:BAX or VDAC:BAK complexes are largely similar ( Fig. 2b and 2c ). VDAC2 appeared critical for the formation of both BAX and BAK complexes ( Fig. 2e and Supplementary Fig. 2e) and for their localization on mitochondria (Fig. 2d) . That VDAC3 played an ancillary role (Fig. 2d, 2e and Supplementary Fig. 2e ), suggests a functional hierarchy between the VDACs and implies a potential topology of the mitochondrial complexes (Fig. 2f) . Consistent with this notion, we found that VDAC2 had the greatest role in BAX-mediated apoptosis, with VDAC3 playing a lesser role, and VDAC1 largely dispensable (Fig. 2g ). This clear functional distinction between VDAC2 and VDAC1 for BAX to function allowed us to clarify how VDAC2 might promote the activity of BAX.
A distinct surface on VDAC2 drives BAX activity
Of note, re-expression of VDAC2, but not VDAC1, rescued BAX complex formation in VDAC2-deficient cells (Fig. 3a) . Moreover, while VDAC2 could rescue BAX driven apoptosis, VDAC1 could not (Fig. 3b) . We exploited this distinctive functional impact when these closely related VDACs were expressed to map the precise region on VDAC2 necessary to promote BAX activation. To do this, we generated and expressed VDAC1/2 chimeras ( Fig. 3c and Supplementary Fig. 2f ). We identified a region of VDAC2, comprising central β-strands 7-10 that was sufficient to promote BAX apoptotic function (Fig. 3d) , as well as support the formation of BAX complexes in the mitochondrial membrane (Fig. 3e ).
Taken together, we postulate that a distinct surface on VDAC2 is required for the recruitment of BAX to the mitochondria and that disrupting this completely abrogates BAX function ( Figs. 3f and 3g) . Interestingly, the same region of VDAC2 appears to mediate its interaction with BAK 14 , suggesting a conserved mechanism for recruiting both BAX and BAK to mitochondria. However, the functional impact of Vdac2 deletion on the apoptotic function of BAX and BAK differs. That BAK still drives apoptosis without VDAC2 (Figs. 1c, 1d and 2g ),
indicates that VDAC2 is not the sole conduit for BAK to the MOM where it acts (Fig. 3g) .
Conversely, VDAC2 is essential for BAX recruitment to mitochondria and its absence nullifies BAX apoptotic function (Fig. 3g) .
BAK does not limit embryonic development of Vdac2 -/-mice
Contrary to our studies uncovering the essential role of VDAC2 in promoting BAX-mediated apoptosis, it had been reported that VDAC2 inhibits BAK 15 . Hence, it was proposed that the early embryonic lethality upon deleting Vdac2 is caused by inappropriate and excessive apoptosis driven by unrestrained BAK 15 . If so, we should expect that co-deleting Bak should allow Vdac2-null embryos to survive. To test this hypothesis, we injected C57BL/6 zygotes with plasmid encoding Cas9 together with short guide RNAs targeting Bak and Vdac2 (Fig. 4a) . The resulting embryos were harvested at E14.5 and although all appeared grossly normal (data not shown), genotyping of these embryos was revealing. Most embryos were Vdac2-null (87.5%), yet concomitant Bak deletion was only observed in 8% compared with 23% when Bak was targeted alone (Fig. 4a) . This suggested that co-deletion of Bak neither promoted nor was it essential for the survival of Vdac2 -/-embryos, at least up to the E14.5 developmental stage.
Since a significant number of Vdac2 -/-embryos survived to E14.5, we set out to determine whether its loss might compromise development later during embryogenesis. Vdac2
-/-mice were generated on a C57BL/6 genetic background and we allowed the mice to develop to term (Fig. 4b) . Of the 26 surviving offspring, 20 were Vdac2 knock-out with homozygous non-sense (indels) mutations ( Supplementary Fig. 3a ). The absence of VDAC2 protein was confirmed by mass spectrometry and immunoblotting of liver extracts from Vdac2 -/-mice ( Supplementary Fig. 3b ). Thus, the early embryonic lethality associated with deleting Vdac2 must depend on genetic background, being much more severe in 129Sv;C57BL/6 mice 15 compared to the inbred C57BL/6 used here.
Vdac2 -/-mice do not exhibit evidence of excessive BAK-mediated apoptosis
Although Vdac2 -/-mice were viable at birth, they failed to gain weight and had to be euthanized by 6 weeks of age because of ill health (Fig. 4c, 4d and Supplementary Fig. 3c ). Regardless, this provided us with an opportunity to investigate the interaction between VDAC2 and BAK in vivo in addition to that during embryogenesis, focusing initially on testing if VDAC2 acts to restrain BAK 15 . Firstly, it is well recognized that BAK-mediates cytochrome c release, indicative of mitochondrial outer membrane damage, when mouse liver mitochondria (MLM) are treated with BH3 peptides such as cBID 21 . Surprisingly, this was not enhanced by the deletion of Vdac2 ( Fig.   4e and Supplementary Fig. 3d ), but was instead compromised, most probably because BAK levels are reduced in Vdac2-null cells (Supplementary Figs. 3e and 3f) 13, 22 .
Secondly, platelet homeostasis is highly dependent on BAK; its deletion causes elevated platelet counts whereas unrestrained BAK leads to low platelet counts 23 . If VDAC2 acts to restrain BAK by their association in platelets ( Supplementary Fig. 4a ), then deleting VDAC2
should decrease platelet counts, but this was not the case (Fig. 4f) Fig. 4c ). This suggested that the overall reduction in white and red blood cell counts in Vdac2 -/-mice (Fig. 4f ) is secondary to their overall ill health rather than due to excessive BAK-mediated apoptosis. 
VDAC2 is required for BAX to mediate tumor cell killing by chemotherapy
Given that our data unequivocally implicates a central role for VDAC2 in promoting BAX-mediated apoptosis, we hypothesized that the BAX:VDAC2 interaction would also be important for the action of BAX in response to chemotherapeutic agents. Apoptosis of HCT116 colorectal cancer cells in response to either ABT-737 27 or the BCL-X L inhibitor A1331852 relies on BAX (Fig. 5a ). Deletion of VDAC2 rendered HCT116 cells as resistant to these BH3-mimetic compounds as the loss of BAX alone and remarkably, even the combined loss of BAX and BAK ( Fig. 5a and Supplementary Fig. 5a ). When apoptosis in the same cells could be also driven by BAK (e.g. combining ABT-737 with actinomycin D treatment), the loss of VDAC2 alone had no impact ( Fig. 5a ).
Similarly, killing of the acute lymphoblastic leukemia cell line RS4;11 induced by the BCL-2 inhibitor venetoclax (also known as ABT-199) 7, 9 , or standard-of-care chemotherapeutic agents is principally mediated by BAX ( 
VDAC2 is required for BAX to limit tumor formation
As the intrinsic apoptotic pathway is an important barrier to tumorigenesis, we hypothesized that the impairment of BAX-mediated apoptosis by deletion of Vdac2, when combined with Bak deletion, should accelerate tumor development. Fetal liver-derived HSCs derived from Bak
-/-mice at E14.5 were retrovirally transduced with the c-MYC oncogene and transplanted into lethally-irradiated mice to induce acute myeloid leukemia (AML) ( Fig. 6 and Supplementary Fig. 6 )
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. As expected, the combined loss of Bax and Bak in hematopoietic progenitors accelerated the development of MYC-driven AML compared with loss of Bak alone (Fig. 6) . Strikingly, the combined deletion of Vdac2 and Bak also accelerated AML development when compared with deletion of Bak alone (Fig. 6 ), affirming that VDAC2 is a key driver of BAX activation in the context of oncogenic stress.
Discussion
Detailed understanding of how intrinsic apoptosis is controlled has paved the way for the development and clinical success of small molecule agonists of the pathway, such as the BCL-2 inhibitor, venetoclax (ABT-199) to treat certain cancers 7, 9, 30 . BAX and BAK act in a functionally redundant manner to mediate intrinsic apoptosis triggered by venetoclax and also during normal tissue homeostasis. Hence, how these essential cell death mediators are regulated is critical both for understanding normal cell death control and for our efforts to target this pathway for therapeutic benefit.
In this regard, VDAC2 plays an intriguing and controversial role. A previous report suggested that VDAC2 restrains BAK and that the early embryonic lethality observed in Vdac2-deficient mice is potentially due to unrestrained BAK activity 15 . Unlike the mice on a mixed genetic background used in that study, we found instead that Vdac2-null mice on an inbred C57BL/6 genetic background were viable at birth, although they failed to thrive postnatally ( do not exhibit such a liver phenotype or premature decline, implies a non-redundant isoformspecific function for VDAC2 15, 33, 34 . In the context of our study, we failed to find any evidence of heightened sensitivity to apoptosis in various cell types, which would have been expected if BAK was left unrestrained by the loss of VDAC2. Definitive conclusions about the role of VDAC2 in controlling apoptosis in vivo are complicated by its dual functions in metabolite transport and in apoptosis and the significant impact of Vdac2 deletion on the overall health of knockout mice. However, our studies suggest that the loss of Vdac2 does not promote BAKmediated apoptosis: 1) platelet number was not reduced (Fig. 4f) ; 2) liver mitochondria were not more sensitive to cytochrome c release when treated with cBID (Fig. 4e) ; 3) there was no increase in blood cell apoptosis ex vivo ( Supplementary Fig. 4c ).
In parallel studies and in accord with other reports 13, 19, 22 , we confirmed that BAX and BAK interact with VDAC2 on the MOM through a conserved mechanism (Fig. 3) . However, the sharply contrasting consequences of blocking VDAC2-driven mitochondrial recruitment on the apoptotic activity of BAX or BAK was completely unanticipated. Using a range of in vitro and in vivo systems, we discovered that this step is crucial specifically for BAX, but not BAK, to mediate apoptosis. Thus, where BAX is the key mediator of apoptotic cell death, we found identical consequences when either BAX or VDAC2 were genetically deleted. For example, BAX-mediated killing of cancer cells by venetoclax was completely abrogated in the absence of VDAC2. Consistent with these observations we noted defective spermatogenesis upon deleting
Vdac2, a phenotype reminiscent of Bax loss 26 . Based on our studies, we conclude that VDAC2 is essential for recruiting BAX to mitochondria.
Given the proposed redundancy between BAX and BAK, it is somewhat surprising that deleting VDAC2 did not impair BAK activity. This may be because, although VDAC2 plays a role in the localization of BAK to mitochondria 13 , it may not be solely responsible. Properties inherent to BAK itself, such as its C-terminal tail or other factors on the MOM could act independently of VDAC2 to promote BAK localization to mitochondria and hence its apoptotic activity (Fig. 3g) . Intriguingly, the removal of VDAC2 renders BAK hyper-active in some situations 13, 15 . A possible explanation is that both BAX and BAK need to dissociate from VDAC2 to homo-oligomerize to mediate cytochrome c release 12, 13 . As the residual population of BAK that targets mitochondria independent of VDAC2 does not have to undergo this rate- 
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Materials & Methods
Animal models
All mice were in an inbred C57BL/6J genetic background. All animal experiments conformed to the regulatory standards of, and were approved by, the Melbourne Health Research Directorate Animal Ethics Committee.
Isolation of mouse liver mitochondria
The isolation of mitochondria from the livers of 4-6 week old mice was performed as 43 . To identify genes whose sgRNAs had become significantly enriched in the surviving cell population, sgRNAs were ranked in descending order after calculating residuals to a lowest smoothed line fitted to log2-normalized counts for each sgRNA before and after selection. Minimum hypergeometric P-values were calculated from this ranked list for each gene represented in the library using an established algorithm 45 and corrected for multiple testing.
Subcellular fractionation, mitochondrial isolation, SDS-PAGE, blue native PAGE and immunoblotting
Cytosol and mitochondria-enriched heavy membrane fractions were fractionated following cell membrane permeabilization with 0.025% w/v digitonin as described 46 . Alternatively, mitochondria were isolated by homogenization following hypotonic cell swelling as described (Stojanovski et al, 2003) .
For SDS-PAGE, lysates of whole cells or cellular fractions in reducing Laemmli sample buffer were electrophoresed through Tris-glycine gels (BioRad) and transferred to PVDF membrane.
Blue native PAGE was performed as described 47 . Proteins were transferred to PVDF, and blots were destained in 50% methanol and 25% acetic acid prior to immunoblotting. 
Generation of CRISPR/Cas9 gene-targeted mice
CRISPR/Cas9 generation of the Vdac2/Bak/Rosa mutant mice was performed as previously described 48, 49 . Briefly, Cas9 mRNA (20 ng/μl) and sgRNA (10 ng/μl; for sgRNA) were injected into the cytoplasm of fertilized one-cell stage embryos. 24 hours later, two-cell stage embryos were transferred into the uteri of pseudo-pregnant female mice. Viable offspring were genotyped by next-generation sequencing as previously described 43 .
Blood and histological analysis of mice
Automated cell counts were performed on blood collected from the retro-orbital plexus into tubes containing EDTA (Sarstedt), using an Advia 2120 hematological analyzer (Siemens).
Tissues were fixed in formalin, embedded, sectioned, and stained with hematoxylin and eosin. Fifteen min after administration of luciferin mice were anaesthetized with isoflurane inhalant and imaged using the IVIS live-imaging system (Perkin Elmer). Tumor burden was quantified by measuring the total photon flux per second emitted from the whole mouse.
Mouse model of chemoresponse and tumor development
To investigate tumor development, fetal liver-derived hematopoietic stem cells were harvested from mice (all on a C57BL/6 genetic background) at E14. ng/mL IL-6, 50 ng/mL thrombopoietin, 5 ng/mL fms-related tyrosine kinase 3 ligand). Cells were then injected into lethally-irradiated (2 × 5.5 Gy, 2 h apart) recipient C57BL/6 mice. Mice were euthanized upon signs of illness (enlarged spleen or lymph nodes and weight loss). Each fetal liver was reconstituted into 6 lethally-irradiated mice with mice dying of irradiation toxicity (usually within 2 weeks) was censored from the analyses.
Mass spectrometry and data analysis
Frozen livers were homogenized and solubilized in 1% Triton X-100. Proteins were resuspended in 6 M Urea, 100 mM DTT and 100 mM Tris-HCl pH7.0 and subjected to protein digestion using filter aided sample preparation 50 . Peptides in MilliQ water containing 1% acetonitrile (ACN) and 1% formic acid were analyzed by nanoflow liquid chromatography For the analysis of the mitochondrial BAX/BAK complexes, mitochondria from MEFs expressing FLAG-BAK, FLAG-BAX S184L or untagged BAX or BAK as controls were solubilized in 1% digitonin and immunoprecipitated with anti-FLAG-coupled sepharose.
Proteins were eluted with FLAG peptide in the presence of 1% digitonin, run on BN-PAGE, and stained using Sypro Ruby (Bio-Rad) and subsequently Coomassie G-250. Bands of interest were excised and subjected to in-gel reduction, alkylation, and trypsin digestion before mass spectrometry analysis as previously described 51 . Peptides from each biological replicate were run in technical triplicate, separated by reverse-phase chromatography on a 1. Mass spectra were acquired in a data-dependent manner including an automatic switch between MS and MS/MS scans using a 1.5 second duty cycle and 4 Hz MS1 spectra rate followed by MS/MS scans at 8-20 Hz dependent on precursor intensity for the remainder of the cycle. MS spectra were acquired between a mass range of 200-2000 m/z. Peptide fragmentation was performed using collision-induced dissociation (CID). The raw files were analyzed using the MaxQuant software (version 1.5.2.8) 52, 53 , and extracted peaks were searched against UniProtKB/Swiss-Prot Mus musculus database (July 2015) containing sequences for human BAK1 and human VDAC2 and human BAX, as well as a separate reverse decoy database to empirically assess the false discovery rate (FDR) using strict trypsin specificity allowing up to 2 missed cleavages. The minimum required peptide length was set to 7 amino acids. In the main search, precursor mass tolerance was 0.006 Da and fragment mass tolerance was 40 ppm. The search included variable modifications of oxidation (methionine), amino-terminal acetylation, the addition of pyroglutamate (at N-termini of glutamate and glutamine) and a fixed modification of carbamidomethyl (cysteine). PSM and protein identifications were filtered using a targetdecoy approach at a false discovery rate of 1%. Statistically-relevant protein expression changes between the samples were identified using a custom in-house designed pipeline as previously described 54 where quantitation was performed at the peptide level. Probability values were corrected for multiple testing using Benjamini-Hochberg method. Cut-off lines with the function y= -log 10 (0.05)+c/(x-x 0 ) 55 were introduced to identify significantly enriched proteins. c was set to 0.2 while x 0 was set to 1, representing proteins with a twofold (log2 protein ratios of 1 or more)
or fourfold (log2 protein ratio of 2) change in protein expression, respectively.
Bone marrow-derived hematopoietic precursor reconstitution
Bone-marrow was harvested from the femurs of Vdac2 -/-or age-matched wild-type control mice. Single cell suspensions were frozen at -80°C in 90% FCS/10% DMSO until reconstitution.
C57BL/6 Ly5.1 mice were lethally-irradiated with 2 x 5.5 Gy 2 h apart and reconstituted with intravenous injection of hematopoietic precursors harvested from the bone marrow of Vdac2 -/-or age-matched C57BL/6 wild-type mice in PBS. Mice were sacrificed 8 weeks post-reconstitution and blood cell analysis was performed.
Thymocyte and splenocyte isolation and characterization
Thymus and spleen were harvested from Vdac2 -/-or age-matched wild-type control mice and single cell suspensions were generated by gentle homogenization through a 100 μm sieve. 
Platelet isolation and treatment
Platelets were isolated essentially as previously described 56 . Peripheral blood was obtained by cardiac puncture into 0.1 volume of Aster Jandl citrate-based anticoagulant (85 mM sodium citrate, 69 mM citric acid, and 20 mg/ml glucose, pH 4.6). Platelet-rich plasma was obtained by centrifugation of the murine blood diluted in buffer A (140 mM NaCl, 5 mM KCl, 12 mM trisodium citrate, 10 mM glucose, and 12.5 mM sucrose, pH 6.0) at 125 g for 8 min at room temperature. The supernatant was followed centrifuged at 860 g for 5 min and platelets were resuspended in 10 mM Hepes, 140 mM NaCl, 3 mM KCl, 0.5 mM MgCl 2 , 10 mM glucose, and 0.5 mM NaHCO 3 , pH 7.4. 
Statistical analysis
Unless otherwise noted, all experiments used at least three mice per experimental group.
Statistical details of the experiments including statistical tests used can be found in the Figure
Legends. In the cell and animal experiments statistical significance was defined as P<0.05. Mitochondria from MEFs expressing FLAG-BAK or untagged BAK were solubilized in 1% digitonin prior to anti-FLAG affinity purification and proteins identified by mass spectrometry. 
